Marker Therapeutics, Inc. (NASDAQ: MRKR) announced that Kathryn Penkus Corzo, R.Ph., MBA, will join its Board of Directors effective November 1, 2025. Ms. Corzo’s appointment follows a November 5 announcement and brings a seasoned oncology and cell‑therapy executive to a company that is advancing a non‑engineered MAR‑T platform for lymphoma and acute myeloid leukemia.
Ms. Corzo has more than 30 years of biopharma leadership, most recently serving as President and COO of bit.bio Ltd., where she built scalable iPSC‑based manufacturing, and as Head of Oncology Cell Therapy Development at Takeda Ventures, where she led CAR‑T, CAR‑NK, and iPSC programs. Her prior roles at Sanofi Genzyme, Hoffmann‑La Roche, Eli Lilly, and Syndax Pharmaceuticals demonstrate a track record of moving product pipelines from discovery to commercialization, aligning closely with Marker’s goal of bringing its MAR‑T platform to market.
Marker’s lead product, MT‑601, is being studied in the Phase 1 APOLLO program for relapsed or refractory non‑Hodgkin lymphoma, with a 66 % objective response rate reported in early data. The company is also advancing MT‑401‑OTS, an off‑the‑shelf MAR‑T product, in the Phase 1 RAPID trial for post‑transplant AML. In the last twelve months, revenue grew 44.55 % to $X million, while EBITDA remained negative at $8.12 million, reflecting the company’s continued investment in clinical development. Marker’s market capitalization stands at approximately $11.7 million as of the announcement date.
CEO Juan Vera said, “We are pleased to welcome Kathryn to our Board of Directors. We believe in the strong clinical benefit we have observed with our lead asset MT‑601 and remain committed to advancing the APOLLO program toward a future pivotal study in patients with CAR‑relapsed diffuse large B‑cell lymphoma. As we move into the next stage of clinical development, we have decided to strategically strengthen our Board of Directors to support this critical next phase.”
Ms. Corzo added, “I am honored to join Marker’s Board of Directors at such a pivotal time for the company. Marker’s Multi‑Antigen Recognizing T‑cell platform represents a next‑generation approach in cell therapy—addressing key limitations of current treatments with the potential to offer improved clinical outcomes to patients with limited therapeutic options. I am inspired by the team’s scientific rigor and commitment to patients, and I look forward to contributing to the advancement of Marker’s clinical programs and long‑term growth.”
The addition of Ms. Corzo is expected to enhance governance, accelerate go‑to‑market strategies, and strengthen the company’s ability to navigate regulatory and commercial challenges as it progresses toward pivotal trials and potential approvals. Her expertise in oncology, cell‑therapy commercialization, and strategic planning positions Marker to capitalize on the growing demand for safer, more effective T‑cell therapies while managing the financial and operational risks inherent in early‑stage development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.